<DOC>
	<DOC>NCT00733668</DOC>
	<brief_summary>An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.</brief_summary>
	<brief_title>Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Inform consent Male and female, age between 18 and 65 years. Na√Øve to any atypical antipsychotic A diagnosis of major depressive disorder No use of fluvoxamine Patients with a history of bipolar I or II disorder Diagnosis of psychotic major depression disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>considered</keyword>
	<keyword>entry</keyword>
	<keyword>into</keyword>
	<keyword>the study</keyword>
	<keyword>SSRI</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>fumarate</keyword>
	<keyword>antipsychotic</keyword>
</DOC>